Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Apoptosis is the main type of programmed cell death in animals, participating to the modeling of organs during the development, and to tissue homeostasis during the whole life. Is activated after external or internal stimulation and leads to non-inflammatory reactions, opposite to other forms of cell death, such as necrosis. The group of proteins known as Bcl-2 family members are central players of apoptosis, because they form the interface between the early signaling events that cause cells to enter the apoptotic process and the events that later confer apoptosis characteristics to the cells, leading to their elimination by the immune system. Family members of Bcl-2 are characterized by four homologous domains, termed BH1 to BH4. Classically, the Bcl-2 family is divided into three subfamilies: anti-apoptotic proteins (e.g. Bcl-2, Bcl-xL), pro-apoptotic proteins (e.g. Bax, Bak, Bok) and only BH3 proteins (e.g. Bid, Bad).
The homologue function of Bcl-2 is critical for the regulation of mitochondrial outer membrane permeabilization (MOMP), the key event irreversibly engaging the cells towards death. After MOMP, a specific set of proteases is activated. This activation occurs through two processes: (1) procaspase is cleaved into two subunits and recombined into active heterotetramers and (2) IAPs, a family of caspases inhibitors, are inactivated. It is now widely accepted by investigators that MOMP is caused by the formation of large pores on the outer membrane of mitochondria (MOM), which enables the release of several proteins from the mitochondrial intermembrane space to the cytosol. There are five proteins have been identified as ‘apoptogenic factors’. Among the apoptogenic factors, cytochrome c is one of the most ubiquitous and conserved proteins in the whole living world, a feature most certainly related to its central function as a mobile electron carrier that shuttles between respiratory complexes. Therefore, it can be used as a universal mark for MOMP, including in model systems that do not carry out6 canonical apoptosis. Most specifically, the release of cytochrome c became a criterion in the study of the function of Bcl-2 homologs in animals after expression in yeast. The expression of human Bax was shown to promote the release of cytochrome c in yeast even before it was shown in human cells. Like in mammalian cells, several death signals in yeast, such as acetic acid treatment, induces significant mitochondrial morphological changes and non-selective release of membrane clearance proteins, which have homologies with mammalian apoptogenic factors. Interestingly, Bax effects in yeast do not depend on other proteins that are released following death stimuli, such as acetic acid treatment, that may induce a necrotic type of death depending on massive mitochondrial permeabilization resembling mPTP. This supports the view that, in mammalian cells, only cytochrome would be released through Bax-formed channels, while other apoptogenic factors would be released through other systems, such as mPTP or ceramides channels.
Fig. 1. Mitochondrial proteins released during cell death in mammals and yeast. (T.T. Renault et al. Mechanisms of Ageing and Development. 2017).
Bax retrotranslocation
It has long been believed that Bax translocation from the cytoplasm to the mitochondria is a one-way process. This came from the observation that, in non-apoptotic cells, Bax localization is essentially diffuse in the cytosol while, after apoptosis is triggered, it is relocated to mitochondria to form membrane-inserted oligomers that are responsible for MOMP. However, important observations indicate that passage from soluble/monomer Bax to membrane insertion/oligo-Bax expression is not a one-step method. For example, it has been shown that, during anoikis, Bax could be relocalized to mitochondria, but that the process was reversible. T.T. Renault et al. demonstrated that the 'mitochondrial Bax gene' is not a mandatory 'membrane insertion' Bax protein. Structural studies have allowed designing a complex Bax mutant that has a constitutive mitochondrial localization but that cannot support the conformational change associated to the oligomerization, thus remaining incompetent for cytochrome c release. When expressed in HCT-116 or in HeLa cells, the GFP-tagged form of this mutant showed mitochondrial localization and did not trigger apoptosis. After photobleaching of GFP fluorescence in the nucleus, both nuclear and cytoplasmic fluorescence disappeared, while mitochondrial fluorescence remained. This reflected the rapid dynamics of exchange between the nucleus and the cytosol, and its absence for mitochondrial Bax. However, by following the re-appearance of the fluorescence in the cytosol, the authors showed that a fraction of mitochondrial Bax could be retrotranslocated from the mitochondria to the cytosol. Most interestingly, this reverse transposition process is greatly accelerated when the anti-apoptotic protein Bcl-xl is overexpressed. This led the authors to conclude that, in non-apoptotic cells, (1) Bax subcellular localization followed a dynamic equilibrium between mitochondria and cytosol and that (2) anti-apoptotic proteins could displace this equilibrium towards a more cytosolic localization. An additional interesting observation was that a mutant of Bcl-xL deleted of the C-terminal α-helix (Bcl-xLΔC) was unable to promote Bax retrotranslocation, and further experiments demonstrated that the deletion of the last residues of Bcl-xL were sufficient to prevent it.
Fig. 2. Comparison of the effects of full-length Bcl-xL and truncated Bcl-xLΔC on Bax mitochondrial localization. (T.T. Renault et al. Mechanisms of Ageing and Development. 2017).
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.